Bausch + Lomb Corporation Common Shares — Cash Flow (NYSE:BLCO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities 345 M-17 M232 M283 M 340 M Cash from investing activities -215 M-2.11 B-412 M-455 M -469 M Cash from financing activities 81 M2.08 B178 M225 M 174 M Free cash flow 170 M-198 M232 M283 M 340 M

News

Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Bausch & Lomb (NYSE:BLCO)

How COO Is Balancing Premium Lens Growth Against Asia-Pacific Risks?

Is COO Stock Attractive as MyDay Gains Meet Asia-Pacific Pressure

Alignment Healthcare (ALHC) Soars 25.1%: Is Further Upside Left in the Stock?

Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care - Slideshow (NYSE:BLCO) 2026-06-01

Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript

Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios - Slideshow (NYSE:BLCO) 2026-03-23

RBC reiterates Bausch & Lomb stock rating on DED rival delay